/var/www/perpustakaan972/lib/SearchEngine/DefaultEngine.php:610 "Search Engine Debug 🔎 🪲"
Engine Type ⚙️: "SLiMS\SearchEngine\DefaultEngine"
SQL ⚙️: array:2 [ "count" => "select count(distinct b.biblio_id) from biblio as b left join mst_publisher as mp on b.publisher_id=mp.publisher_id left join mst_place as mpl on b.publish_place_id=mpl.place_id where b.opac_hide=0 and (b.biblio_id in(select bt.biblio_id from biblio_topic as bt left join mst_topic as mt on bt.topic_id=mt.topic_id where mt.topic like ?))" "query" => "select b.biblio_id, b.title, b.image, b.isbn_issn, b.publish_year, mp.publisher_name as `publisher`, mpl.place_name as `publish_place`, b.labels, b.input_date, b.edition, b.collation, b.series_title, b.call_number from biblio as b left join mst_publisher as mp on b.publisher_id=mp.publisher_id left join mst_place as mpl on b.publish_place_id=mpl.place_id where b.opac_hide=0 and (b.biblio_id in(select bt.biblio_id from biblio_topic as bt left join mst_topic as mt on bt.topic_id=mt.topic_id where mt.topic like ?)) order by b.last_update desc limit 10 offset 30" ]
Bind Value ⚒️: array:1 [ 0 => "%respiratory tract infections%" ]
Respiratory tract infections are commonly found health problems in daily practice. Various microorganisms may be the causative pathogens and many antimicrobial agents are claimed to be effective to overcome the problem. Rational choice of antimicrobiolal agents should be based on empirical experience what is the most likely pathogen(s) for a particular respiratory tract infection, followed by c…
Ceftibuten is a third generation cephalosporine with beta laktamase resistent properties. The drug is a broad-spectrum, oral and allows a single daily dosage which ensures patient compliance. The properties of ceftibuten is compared to ciprofloxacin for the treatment of bronchitis and pneumonia using a clinical trial with a comparative, paralel group, randomized methode. Ceftibuten was given 40…
A study on the effect of
Cefixime, one of the new third generation oral cephalosporin antibiotic, was evaluated for safety and efficacy in the treatment of 37 patients with non-tuberculous